glp-1 news today obesity drug updates ADA 2026 confirmed what many of us have been anticipating for years. We're entering a new era of medicine: triple agonists, oral GLP-1s, monthly injections, and therapies targeting obesity, diabetes, and GLP-1 Agonists Weight Loss Drugs
Description
(Updated 2/20/2026) Weight-loss medications are evolving rapidly as researchers look for new options beyond the current once-weekly GLP-1 injections
Semaglutide reduced liver fat, inflammation, and fibrosis scores in clinical trials
Rights and permissions This article is published under an open access license
Based on current clinical evidence, tirzepatide (Zepbound) produces the highest average weight loss, followed by semaglutide (Wegovy), and then liraglutide (Saxenda)
A randomized study investigating the effect of omeprazole on the pharmacokinetics of oral semaglutide
These results support the rationale of developing retatrutide as an alternative to semaglutide and/or tirzepatide 5
